Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech’s Series B round will finance clinical tests of two programs, each addressing a different stage of the disease. The post Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD appeared first on MedCity News.
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech’s Series B round will finance clinical tests of two programs, each addressing a different stage of the disease.
The post Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD appeared first on MedCity News.
